Centiva Capital’s AstraZeneca AZN Stock Holding History

Centiva Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,098	Closed	-$570K	–	1674
2025 Q4	$570K	Sell	3,098 -1,067	-26%	-$187K	﹤0.01%	684
2025 Q3	$639K	Buy	+4,165	New	+$630K	0.01%	583
2025 Q2	–	Sell	-2,191	Closed	-$322K	–	1532
2025 Q1	$322K	Sell	2,191 -1,091	-33%	-$158K	0.01%	1044
2024 Q4	$430K	Sell	3,282 -494	-13%	-$69.2K	0.01%	914
2024 Q3	$588K	Buy	+3,776	New	+$610K	0.01%	1137
2024 Q1	–	Sell	-353	Closed	-$47.5K	–	1774
2023 Q4	$47.5K	Buy	353 +6	+2%	+$780	﹤0.01%	1647
2023 Q3	$47K	Buy	+347	New	+$47.4K	﹤0.01%	1608
2023 Q2	–	Sell	-208	Closed	-$30.6K	–	1628
2023 Q1	$28.8K	Buy	+208	New	+$28K	﹤0.01%	1409
2022 Q2	–	Sell	-12,027	Closed	-$1.6M	–	1680
2022 Q1	$1.6M	Buy	+12,027	New	+$1.44M	0.03%	512
2021 Q3	–	Sell	-1,198	Closed	-$143K	–	1271
2021 Q2	$143K	Buy	+1,198	New	+$131K	﹤0.01%	1249
2020 Q1	–	Sell	-7	Closed	-$1K	–	618
2019 Q4	$1K	Sell	7 -676	-99%	-$63.6K	﹤0.01%	790
2019 Q3	$61K	Buy	+683	New	+$59.2K	﹤0.01%	573

Other funds holding AZN

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $148B AUM

Centiva Capital's AZN Position: Q1 2026 in Review

Centiva Capital sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 3,098 shares — an estimated $570K sold.

Centiva Capital first reported a position in AZN in Q3 2019 and held it in 12 quarters. The position peaked at $1.6M in Q1 2022. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Centiva Capital reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Centiva Capital sold 3,098 AstraZeneca shares in Q1 2026, an estimated $570K.
Centiva Capital first reported a position in AstraZeneca in Q3 2019 and held it in 12 quarters.
Centiva Capital's AstraZeneca position peaked at $1.6M in Q1 2022.
1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.